RxDoctor Payments Data

Bindu Singhal, MD

Internal Medicine · San Diego, CANPI 1073546057

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 12 payments — averaging $103.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$193
  • Portola Pharmaceuticals, LLC$126
  • CSL Behring$125
  • Amgen$124
  • Johnson & Johnson$118
  • Boston Scientific$117
  • plus $437 from 5 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$59,380
Medicare patients
92
Services billed
887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate24$12,882
MultaqDronedarone Hcl12$9,912
EntrestoSacubitril/Valsartan12$8,530
XareltoRivaroxaban14$7,707
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,494
Diltiazem 12hr ErDiltiazem Hcl13$2,214
Atorvastatin Calcium80$1,050
Albuterol Sulfate HfaAlbuterol Sulfate12$1,034
Losartan Potassium48$821
Amlodipine Besylate91$714
Metformin Hcl79$683
Risperidone41$629
Metoprolol Succinate40$504
Omeprazole53$457
Glipizide ErGlipizide21$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$118$7,70714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →